Related Experiment Videos
[Autologous cultured skin substitutes]
1Dermatologische Klinik der Universität Bern, Inselspital. thomas.hunziker@insel.ch
Summary
Cultured skin substitutes show promise for treating chronic wounds like leg ulcers. However, regulatory hurdles and healthcare costs impede their widespread clinical adoption despite ongoing research.
Area of Science:
- Cell culture and biomaterial advancements.
- Development of autologous and allogeneic skin substitutes.
Context:
- Tissue-engineered skin substitutes are available for chronic wounds (e.g., vascular leg ulcers, diabetic foot ulcers) and acute defects (e.g., burns).
- Clinical trials have primarily focused on vascular leg ulcers.
- Some products have received regulatory approval for specific indications.
Purpose:
- To review the progress and clinical application of tissue-engineered skin substitutes.
- To identify barriers to the clinical breakthrough of these novel wound therapies.
Summary:
- Skin substitutes, combining cells (keratinocytes, fibroblasts) with biomaterials (fibrin, collagen, hyaluronan), are commercially available.
- Clinical testing has largely concentrated on chronic wounds, with some success in vascular leg ulcers.
- Regulatory requirements for safety and cost-effectiveness, alongside healthcare resource limitations, hinder widespread adoption.
Impact:
- Despite research, the clinical breakthrough of tissue engineering for skin wound treatment is hampered.
- Demonstrating safety and cost-effectiveness is crucial for reimbursement and market penetration.
- Further research is needed to overcome economic and regulatory challenges for broader clinical use.